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In a recent issue of the Southern African Journal of HIV 
Medicine, Pillay and Black1 summarised the trade-offs 
surrounding the safety of efavirenz (EFV) use in pregnancy. 
Highlighting the benefits of each option for the prevention of 
mother-to-child transmission (PMTCT) of HIV proposed by 
the World Health Organization (WHO), the authors argued 
that the South African (SA) government should consider the 
adoption of Option B as national PMTCT policy, and pilot 
projects implementing Option B+ as a means of assessing the 
individual- and population-level effect of the intervention. 
We echo this call and further recommend that ‘optional B+’ 
(i.e. the option to stay on lifelong antiretroviral therapy 
(ART), effectively adopting PMTCT Option B+) be offered 
to pregnant women for their own health after the cessation of 
breastfeeding, following counselling on the benefits and risks 
of the intervention.  In this article we highlight the benefits of 
Options B and B+.
In April 2012, WHO released a programmatic update to the 
use of antiretrovirals (ARVs) for PMTCT and the treatment 
of HIV-positive pregnant women.2 The key findings indicate 
that Options B and B+ are likely to prove preferable to Option 
A for operational, programmatic and strategic reasons. While 
all options recommend initiating triple ARV therapy in HIV-
positive pregnant women with a CD4 count <350 cells/mm3, 
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their recommendations differ for CD4 counts >350 cells/mm3. For 
the latter, Option A promotes: the use of zidovudine (AZT) from 14 
weeks’ gestation, single-dose nevirapine (NVP) at birth, and 7 days 
of AZT/ lamivudine (3TC) postpartum for the mother; and daily 
NVP for the infant until the cessation of breastfeeding or until 4 - 6 
weeks of age if the mother is receiving antiretroviral therapy (ART) 
or is not breastfeeding. Option B recommends ART for the mother 
from 14 weeks’ gestation until birth or the cessation of breastfeeding, 
and the use of NVP for the infant until 4 - 6 weeks of age. Option 
B+ advocates lifelong ART, and NVP for the infant as for Option B. 
The rationale behind these recommendations stems from increasing 
evidence at clinical and programme levels highlighting the benefits 
of a single, standardised regimen to serve PMTCT and the treatment 
of HIV-positive pregnant women. The WHO update reflects earlier 
recommendations from major donors such as the United States 
President’s Emergency Plan for AIDS Relief (PEPFAR),3 and has led 
to the adoption of Option B+ by other high-burden African countries 
including Malawi, Kenya, Uganda, Swaziland and Rwanda, with pilots 
underway in several others.4 Further support for PMTCT Options B 
and B+ are echoed in a newly released report by the United Nations 
Children’s Fund (UNICEF), the Business Leadership Council and the 
Clinton Health Access Initiative.5 WHO further highlights that this 
suggested approach would strengthen the effectiveness of the PMTCT 
programme through improved linkages with ART programmes. 
Options B and B+ are simpler, 
probably safer, and less 
resource-intense than Option A 
Numerous challenges have been experienced with the implementation 
of Option A. In addition to requiring drug changes across the continuum 
of care (antenatal, delivery and postpartum care),1,6 the option 
necessitates the use of different ARVs depending on CD4 count. Option 
A also involves a long period of AZT monotherapy with associated 
potential for developing thymidine analogue (TAM) mutations, and 
it complicates clinical management and delays treatment initiation, 
mostly where access to CD4 count measurement is scarce.
The provision of effective care in SA is challenged by congested 
health facilities and a lack of human resources. Appropriately, Options 
B and B+ reduce the burden on healthcare workers. Option B simplifies 
the delivery of care by ensuring that the same regimen offered to 
pregnant women is the first-line regimen for all adults, with the WHO 
recommendation of EFV for all stages of pregnancy.7 A standardised 
fixed-dose ARV combination throughout antenatal, delivery and 
postpartum care would not only improve continuity of care, but also 
simplify drug forecasting, procurement, supply chain management, 
and stock-out monitoring. The current first-line regimen in SA is 
tenofovir (TDF)/lamivudine (3TC)/efavirenz (EFV); generic single-
pill fixed-dose combinations are registered and most likely to be 
included in SA’s ARV tender for 2013. Despite reassurance from the 
2010 Medical Research Council (MRC) survey showing a reduction of 
mother-to-child transmission of HIV in SA to 2.7%,8 there are concerns 
regarding the feasibility and acceptability of the daily administration 
of nevirapine (NVP) syrup, including multiple reports of associated 
delivery problems. With the hasty cessation of the provision of 
free formula in the public sector, there may be a future increase in 
breastfeeding transmission rates. Strangely enough, this seems to have 
been accepted as a fatality by the National   Strategic Plan (NSP) 2012 - 
2016 target of <2% at birth and <5% at the end of breastfeeding. 
For even further programmatic simplification, Option B+ would 
altogether send one simple and strong message to patients: ‘ART 
for life’ – promoting good adherence and successful ART. Stopping 
ART after the cessation of breastfeeding is likely to lead to confusing 
messages for HIV-infected individuals, their communities and health 
workers. Moreover, there is a risk of developing non-nucleoside reverse 
transcriptase inhibitor (NNRTI) resistance if ART is stopped without tail 
protection (i.e. continuing the 2 remaining ARV drugs for 7 days after 
withdrawal of an NNRTI). The possible field implications of this are not 
yet well understood. While Option B remains simpler than Option A, it 
requires that primary healthcare services: determine the HIV status of 
women at each pregnancy; determine the CD4 count/HIV clinical stage 
before ART initiation at each pregnancy; ensure timeous ART initiation 
at each pregnancy for HIV-positive women; identify intent to breastfeed 
and the duration thereof after each delivery (taking into consideration 
that women are known to breastfeed beyond the initially intended 
period); and ensure that ART is ceased safely after each pregnancy, with 
CD4 count follow-up. Each additional step in the treatment cascade 
increases the risk of patient attrition. A study in SA demonstrated a 33% 
retention rate from first CD4 count to ART initiation.9 Option B also 
recommends ART initiation from 14 weeks’ gestation – assuming that 
women present for care early in pregnancy. Programme data, however, 
show that the majority of women present much later in pregnancy. Many 
of these challenges would be overcome with Option B+.
Treatment interruptions may be harmful
The national fertility rate in SA is 2.5.10 With multiple pregnancies, 
typical in developing countries, women identified as HIV-positive 
tend to be exposed to the potentially harmful repeated initiation and 
discontinuation of ARVs. This is particularly pertinent in other sub-
Saharan countries with much higher fertility rates than SA (e.g. in 
Malawi, with 5 - 6 births per woman).11 In a recent systematic review,12 
unstructured treatment interruptions were associated with a higher risk 
of death and opportunistic infection, a lower probability of increased 
CD4 cell counts, a higher prevalence of neurocognitive impairment, a 
lower health-related quality of life, and an increased risk of virological 
failure and drug resistance. Earlier trials demonstrated that structured 
treatment interruptions were harmful to patients.13,14 Consequently, 
many experts endorse continuous ART for pregnant women, rather 
than stopping and starting therapy with each pregnancy.6 
Early initiation on ART may improve 
outcomes for mothers 
Following increasing supporting evidence and expert opinion, initiation 
of ART at a CD4 count >350 cells/mm3 to reduce morbidity and 
mortality (outside the context of pregnancy) is now recommended in 
US and European guidelines.15,16 However, there is ongoing controversy 
in this regard. While the debate remains open about the individual 
benefits of ART initiation above a CD4 count of 500 cells/ mm3, a 
special case could be made for women of childbearing age in an African 
context. Multiple pregnancies and increased infectious risks serve to 
predispose these women to a rapid decline in CD4 count; hence, there is 
a relatively short time period within which the women’s CD4 counts are 
high enough for the benefits of ARV initiation to be questionable. In a 
study from Zimbabwe, the peri-partum mortality of women with CD4 
counts of 400 - 600 cells/mm3 was 5.4 times higher than for their HIV-
negative counterparts.17 Furthermore, continual increases in maternal 
mortality in SA have been attributed to the AIDS epidemic.18 





Option B+ could reduce early in utero HIV 
transmission
Option B+ ensures that women are already receiving ART for 
subsequent pregnancies, covering the initial weeks and maintaining 
a higher CD4 count. Several studies have demonstrated that the 
lowest risk of transmission is among women who have initiated ART 
before conception in comparison with those who initiate ART during 
pregnancy. The reduced risk of transmission is believed to be as a result 
of reducing the risk of early in utero transmission.19,20 
Horizontal transmission to HIV-negative 
partners
The HIV prevalence among women during their reproductive years 
is particularly high in SA. A study among couples across eastern and 
southern Africa demonstrated a prevalence of stable HIV-discordant 
partnerships of 8 - 31%, with 49% serodiscordance among couples 
with at least one HIV-infected partner.21 In a meta-analysis in sub-
Saharan Africa, the proportion of HIV-positive women in stable HIV-
serodiscordant relationships was 47%, demonstrating that women are 
just as likely as men to be the index partner.22 As demonstrated in the 
HPTN 052 trial,23 ART decreases transmission in HIV-serodiscordant 
couples by 96%. Continuing ART in women between pregnancies 
during their reproductive years would also serve to protect their HIV-
negative partners. This is in line with the new WHO recommendations 
that HIV-positive individuals in serodiscordant partnerships be given 
ART regardless of CD4 count.24 
Cost-effectiveness of treatment scale-up
The expected reductions in the number of infections, morbidity and 
mortality, both in children and adults, through the provision of Option 
B+, will contribute to a decline in overall treatment cost after initial 
funding.25 
Challenges and arguments 
against Option B+
Several arguments against the adoption of Option B+ must be discussed 
when considering the roll-out of this intervention. 
Adherence 
Adherence among HIV-infected pregnant women is probably the 
most challenging issue, for short-course (Option A/B) and lifelong 
therapy.26-29 In a recent meta-analysis of ART adherence during 
and after pregnancy, ART adherence was well below what was 
recommended for adequate virological suppression, especially during 
the postpartum period.30 This has significant implications for the 
success of lifelong treatment, as recommended with Option B+. Loss 
to follow-up among pregnant women initiating ART across SA was 
found to be the greatest in the first 3 months after ART initiation, 
with differences diminishing over time.31 This highlights where 
adherence support is most required. New innovative strategies need 
to be identified and piloted to address this, including: simpler and 
more tolerable ART regimens (TDF – fixed dose and combination); 
a reduced number of clinic visits and time associated with such visits; 
and adherence support clubs to optimise peer support. 
We suggest an ‘opt-out’ option at the end of the breastfeeding 
period for women with a CD4 count >350 cells/mm3 who do not 
want to remain on ART, allowing structured ART cessation with tail 
protection.
Cost
ARV drug cost was a major determinant in the decision of many sub-
Saharan countries to implement PMTCT Option A. In 2009, the average 
drug cost for implementing Option B was 3 - 5 times higher than that 
of Option A. However, by the end of 2011, the cost was only twice as 
high.2 The annual cost of the TDF/3TC/EFV first-line regimen in SA 
is R1 361.45 (approximately US$162) per patient. A single-pill fixed-
dose regimen costs only marginally more: R1 424.88 (approximately 
US$172) per patient.32 The lowest international price is R828 (US$100) 
per patient, and further reductions are expected. With the opening of 
the SA ARV tender in October 2012, fixed-dose combination drugs are 
likely to become available in the public sector. Further studies by the 
United States Centre for Disease Control (CDC) show that Option B+ 
would cost marginally more than Option B (incremental cost of $270 at 
5 years) in the case of multiple pregnancies.33
Risk of renal toxicity from TDF
TDF has the potential for renal toxicity. While pregnancy-related 
conditions such as hypertension, pre-eclampsia and diabetes increase 
the risk of renal impairment,34 this is offset by the young age of pregnant 
women. Furthermore, Option B+ policy ensures that most women start 
ART early in their HIV infection. Concerns remain surrounding the 
effect of TDF exposure on infant growth, with limited available data.35
Conclusion
Recently, SA’s National Strategic Plan considered the evidence to be 
insufficient to warrant a change from the current PMTCT Option A 
protocol. The WHO programmatic update concludes that both Options 
B and B+ offer programmatic and operational advantages that would 
go towards the elimination of mother-to-child HIV transmission. The 
implementation of Option B+ would require increased adherence 
support mechanisms, funding, and scale-up at the primary healthcare 
level, including the adoption of task-shifting for ART initiation. However, 
this would result in the best protection for the health of pregnant women 
and infants, and contribute to reduced HIV transmission among sero-
discordant couples according to the latest evidence.23 In the medium 
term, this strategy is highly likely to be cost-effective.
Further research is required to address the challenges faced by 
PMTCT programmes while drawing on the latest scientific evidence to 
ensure that it is translated into policies reflecting the needs and realities 
of the millions of women living with HIV and their children. SA’s 
PMTCT programme must ensure the delivery of the best care possible 
and move towards the elimination of paediatric HIV. A more aggressive 
PMTCT option such as B+ should be tested urgently, as it may be a 
necessary step to reach this goal.
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